Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGEN1777 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Monotherapy with AGEN1777 | EXPERIMENTAL | 3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days \[3 weeks\]). |
| AGEN1777 in combination with a PD-1 inhibitor | EXPERIMENTAL | 3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days. |
| Name | Type | Description |
|---|---|---|
| AGEN1777 | DRUG | An immunoglobulin gamma (IgG1) antibody |
| a PD-1 inhibitor | DRUG | Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody |
Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumor for which no acceptable standard therapy available or progressed on or after standard therapies. 2. Measurable disease on baseline imaging based on Response Evaluation Criter...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AGEN1777 is an investigational small molecule being developed for the treatment of advanced cancer. It is intended for use in patients with advanced solid tumors. The drug is currently in clinical development and has not been approved by regulatory authorities.
AGEN1777 is being developed by Agenus Inc., a biopharmaceutical company. Agenus is publicly traded under the ticker symbol AGEN on the stock market. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
AGEN1777 is in Phase 1 clinical development. It has completed a Phase 1 trial, and the drug remains investigational. It is not yet approved by the FDA or other regulatory agencies, and further clinical studies may be needed to establish its safety and effectiveness.
AGEN1777 has been studied in a Phase 1 clinical trial with the identifier NCT05025085. This trial was titled 'A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors' and enrolled 25 participants in the United States. The trial has been completed.
AGEN1777 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial evaluated the drug in patients with advanced solid tumors, but the drug has not yet received marketing approval from the FDA or any other regulatory authority.